Mirum Pharmaceuticals Inc (MIRM) - News Archive

In an exciting development for patients suffering from progressive familial intrahepatic cholestasis (PFIC), Mirum Pharmaceuticals, Inc. announced that LIVMARLI (Maralixibat), an oral solution, has received market appro...

Mirum Pharmaceuticals Achieves Milestone with Significant Revenue Growth Foster City, California Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has announced that the European Commission has granted marketing authorization...

Mirum Pharmaceuticals: Long-Term LIVMARLI Data Highlights Positive Outcomes at EASL Congress in Milan Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) recently unveiled significant findings at the Annual Congress of the Europ...

Mirum Pharmaceuticals Receives Positive CHMP Opinion for LIVMARLI (Maralixibat) Oral Solution in Treating Progressive Familial Intrahepatic Cholestasis in Patients as Young as Three Months Foster City, California, USA A...

Recent advancements in the field of pharmaceutical sciences have led to numerous breakthroughs in the treatment of various medical conditions. In this regard, Mirum Pharmaceuticals, a leading pharmaceutical company, has...